Migraine therapy during pregnancy and lactation

Expert Opinion on Drug Safety

Volumn 9, Issue 6, 2010, Pages 937-948

  Cassina, Matteo ^a   Di Gianantonio, Elena ^a   Toldo, Irene ^a   Battistella, Pier Antonio ^a   Clementi, Maurizio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Lactation; Migraine; Pregnancy; Teratogen

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CINNARIZINE; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOMPERIDONE; ELETRIPTAN; FLUNARIZINE; FROVATRIPTAN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC TROMETAMOL; METOCLOPRAMIDE; NAPROXEN; NARATRIPTAN; NIFEDIPINE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PARACETAMOL; PIROXICAM; PIZOTIFEN; PROCHLORPERAZINE; PROMETHAZINE; RIZATRIPTAN; SUMATRIPTAN; UNINDEXED DRUG;

ACUPUNCTURE; ANOREXIA; APNEA; BILE DUCT ATRESIA; BIRTH DEFECT; BODY TEMPERATURE DISORDER; BRADYCARDIA; BREAST MILK; CHIROPRACTIC; CLEFT LIP; COGNITIVE THERAPY; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL HEART MALFORMATION; CRYING; CYANOSIS; DEHYDRATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEEDBACK SYSTEM; FEEDING DISORDER; FETOTOXICITY; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; GASTROSCHISIS; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPERREFLEXIA; HYPNOSIS; HYPOGLYCEMIA; HYPOTENSION; INFORMATION RETRIEVAL; INTRAUTERINE GROWTH RETARDATION; IRRITABILITY; LACTATION; LIMB DEFECT; LOW BIRTH WEIGHT; MATERNAL AGE; MIGRAINE; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NONHUMAN; OLIGOHYDRAMNIOS; PREGNANCY; PREMATURITY; PRENATAL DRUG EXPOSURE; PROPHYLAXIS; PUBLICATION; PYLORUS STENOSIS; QT INTERVAL; RELAXATION TRAINING; RESPIRATORY DISTRESS; REVIEW; RISK ASSESSMENT; SEIZURE; TERATOGENICITY; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREMOR; VASOCONSTRICTION; VOMITING;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIEMETICS; FEMALE; HUMANS; LACTATION; MIDDLE AGED; MIGRAINE DISORDERS; PREGNANCY; TRYPTAMINES; YOUNG ADULT;

EID: 77958037004     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.505601     Document Type: Review

References (131)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
2. The National Headache Foundation. Available from: www.headache.org/
3. Olesen J, Goadsby PJ, Ramadan NM, et al. The Headaches. 3rd edition. Williams & Wilkins, Philadelphia, Lippincott; 2006
4. Brandes JL. Headache related to pregnancy: management of migraine and migraine headache in pregnancy. Curr Treat Options Neurol 2008;10:12-19
5. Melhado EM, Maciel JA Jr, Guerreiro CAM. Headache during gestation: Evaluation of 1101 women. Can J Neurol Sci 2007;34:187-192
6. Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003;23:197-205
7. Maggioni F, Alessi C, Maggino T, et al. Headache during pregnancy. Cephalalgia 1997;17:765-769
8. Granella F, Sances G, Zanferrari C, et al. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993;33:385-389
9. Silberstein SD. Migraine and pregnancy. Neurol Clin 1997;15:209-231
10. Wainscott G, Sullivan FM, Volans GN, et al. The outcome of pregnancy in women suffering from migraine. Postgrad Med J 1978;54:98-102
11. Granella F, Sances G, Pucci E, et al. Migraine with aura and reproductive life events: a case control study. Cephalalgia 2000;20:701-707
12. Banhidy F, Acs N, Horvath-Puho E, et al. Pregnancy complications and delivery outcomes in pregnant women with severe migraine. Eur J Obstet Gynecol Reprod Biol 2007;134:157-163
13. Chen HM, Chen SF, Chen YH, et al. Increased risk of adverse pregnancy outcomes for women with migraines: a nationwide population-based study. Cephalalgia 2009;30:433-438
14. Nezvalova-Henriksen K, Spigset O, Nordeng H. Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study. Cephalalgia 2009;29:1267-1276
15. Schardein JL. Chemically induced birth defects. 2nd edition. Marcel Deker, New York; 1993
16. Pesaturo KA, Wooding FG. Modern management of the migraine headache. Am J Lifestyle Med 2009;3:147-159
17. Linde K, Allais G, Brinkhaus B, et al. Acupuncture for tension-type headache. Cochrane Database Syst Rev 2009;(1):CD007587
18. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol 2009;16:968-981
19. Killick S, Elstein M. Pharmacologic production of luteinized unruptured follicles by prostaglandin synthetase inhibitors. Fertil Steril 1987;47:773-777
20. Nielsen GL, Sorensen HT, Larsen H, et al. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001;322:266-270
21. Li DK, Liu LY, Douh R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Br Med J 2003;327:368-371
22. Nielsen GL, Skriver MV, Pedersen L, et al. Danish group reanalyses miscarriage in NSAID users. Br Med J 2004;328:109
23. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992;45:361-367
24. Torfs CP, Katz EA, Bateson TF, et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996;54:84-92
25. Martinez-Frias ML, Rodriguez-Pinilla E, Prieto L. Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology 1997;56:241-243
26. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002;155:26-31
27. Kozer E, Nikfar S, Costei A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Obstet Gynecol 2002;187:1623-1630
28. Ericson A, Kallen BAJ. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371-375
29. Ofori B, Oraichi D, Blais L, et al. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006;77:268-279
30. Momma K, Hagiwara H, Konishi T. Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs: study of additional 34 drugs. Prostaglandins 1984;28:527-536
31. Norton ME, Merrill J, Cooper B, et al. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993;329:1602-1607
32. Vermillion ST, Scardo JA, Lashus AG, et al. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Obstet Gynecol 1997;177:256-259
33. Vandenveyver IB, Moise KJ, Ou CN, et al. The effect of gestational-age and fetal indomethacin levels on the incidence of constriction of the fetal ductus-arteriosus. Obstet Gynecol 1993;82:500-503
34. Norton ME. Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology 1997;56:282-292
35. Levin DL, Fixler DE, Morriss FC, et al. Morphologic analysis of the pulmonary vascular bed in infants exposed in utero to prostaglandin synthetase inhibitors. J Pediatr 1978;92:478-483
36. Moise KJ Jr, Huhta JC, Sharif DS, et al. Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med 1988;319:327-331
37. Alano MA, Ngougmna E, Ostrea EM, et al. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:519-523
38. Zenker M, Klinge J, Kruger C, et al. Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: a case report. J Perinat Med 1998;26:231-234
39. Mas C, Menahem S. Premature in utero closure of the ductus arteriosus following maternal ingestion of sodium diclofenac. Aust NZ J Obstet Gynaecol 1999;39:106-107
40. Rein AJ, Nadjari M, Elchalal U, et al. Contraction of the fetal ductus arteriosus induced by diclofenac - case report. Fetal Diagn Ther 1999;14:24-25
41. Corby DG. Aspirin in pregnancy: maternal and fetal effects. Pediatrics 1978;62:930-937
42. Hernandez-Diaz S, Garcia-Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001;110(Suppl 3A):20S-7S
43. Hickok DE, Hollenbach KA, Reilley SF, et al. The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol 1989;160:1525-30; discussion 1530-1531
44. van der Heijden B, Gubler MC. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol 1995;9:675
45. Rumack CM, Guggenheim MA, Rumack BH, et al. Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet Gynecol 1981;58:52S-6S
46. Baerts W, Fetter WP, Hop WC, et al. Cerebral lesions in preterm infants after tocolytic indomethacin. Dev Med Child Neurol 1990;32:910-918
47. Doyle NM, Gardner MO, Wells L, et al. Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis. J Perinatol 2005;25:336-340
48. [Anon]CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994;343:619-629
49. Di Sessa TG, Moretti ML, Khoury A, et al. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 1994;171:892-900
50. Walter K, Dilger C. Ibuprofen in human milk. Br J Clin Pharmacol 1997;44:211-212
51. Weibert RT, Townsend RJ, Kaiser DG, et al. Lack of ibuprofen secretion into human milk. Clin Pharm 1982;1:457-458
52. Rebordosa C, Kogevinas M, Bech BH, et al. Use of acetaminophen during pregnancy and risk of adverse pregnancy outcomes. Int J Epidemiol 2009;38:706-714
53. Cleves MA, Savell VH Jr, Raj S, et al. Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Defects Res A Clin Mol Teratol 2004;70:107-113
54. McElhatton PR, Sullivan FM, Volans GN, et al. Paracetamol poisoning in pregnancy: an analysis of the outcomes of cases referred to the Teratology Information Service of the National Poisons Information Service. Hum Exp Toxicol 1990;9:147-153
55. McElhatton PR, Sullivan FM, Volans GN. Paracetamol overdose in pregnancy analysis of the outcomes of 300 cases referred to the Teratology Information Service. Reprod Toxicol 1997;11:85-94
56. Thulstrup AM, Sorensen HT, Nielsen GL, et al. Fetal growth and adverse birth outcomes in women receiving prescriptions for acetaminophen during pregnancy. Am J Perinatol 1999;16:321-326
57. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-789
58. World Health Organization. Breastfeeding and Maternal Medication; 2002
59. Banhidy F, Acs N, Puho E, et al. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth. Br J Clin Pharmacol 2007;64:510-516
60. Soldin OP, Dahlin J, O'Mara DM. Triptans in pregnancy. Ther Drug Monit 2008;30:5-9
61. Nezvalova-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from The Norwegian Mother and Child Cohort Study. Headache 2010;50:563-575
62. Hogberg U, Wang M. SSRI during pregnancy and risk of fetal neurotoxicity. Follow precautions and look for other therapeutic alternatives. Lakartidningen 2005;102:113-115
63. Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 2003;17:1-7
64. Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special to sumatriptan. Headache 2001;41:351-356
65. Cunnington M, Ephross S, Churchill P. The safety of sumatriptan and naratriptan in pregnancy: what have we learned? Headache 2009;49:1414-1422
66. Fiore M, Shields KE, Santanello N, et al. Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia 2005;25:685-688
67. Lucas S. Medication use in the treatment of migraine during pregnancy and lactation. Curr Pain Headache Rep 2009;13:392-398
68. Matok I, Gorodischer R, Koren G, et al. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 2009;360:2528-2535
69. Berkovitch M, Elbirt D, Addis A, et al. Fetal effects of metoclopramide therapy for nausea and vomiting of pregnancy. N Engl J Med 2000;343:445-446
70. Berkovitch M, Mazzota P, Greenberg R, et al. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. Am J Perinatol 2002;19:311-316
71. Sorensen HT, Nielsen GL, Christensen K, et al. Birth outcome following maternal use of metoclopramide. The Euromap study group. Br J Clin Pharmacol 2000;49:264-268
72. Askenasy JJ, Streifler M, Felner S. The synaptic significance of metoclopramide induced dyskinetic-dystonic head and neck movements in pregnancy. J Neural Transm 1978;42:73-84
73. Moos DD, Hansen DJ. Metoclopramide and extrapyramidal symptoms: a case report. J Perianesth Nurs 2008;23:292-299
74. Dubow JS, Leikin J, Rezak M. Acute chorea associated with metoclopramide use. Am J Ther 2006;13:543-544
75. van der Padt A, van Schaik RH, Sonneveld P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth J Med 2006;64:160-162
76. Yis U, Ozdemir D, Duman M, et al. Metoclopramide induced dystonia in children: two case reports. Eur J Emerg Med 2005;12:117-119
77. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005;26:720-723
78. Djeddi D, Kongolo G, Lefaix C, et al. Effect of domperidone on QT interval in neonates. J Pediatr 2008;153:663-666
79. Eghbali M, Wang Y, Toro L, et al. Heart hypertrophy during pregnancy: a better functioning heart? Trends Cardiovasc Med 2006;16:285-291
80. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009;15:183-192
81. Einarson A, Maltepe C, Navioz Y, et al. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004;111:940-943
82. Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010;182:E269-76
83. Schroeder BM; AAFP, ACP-ASIM. AAFP/ACP-ASIM release guidelines on the management and prevention of migraines. Am Fam Physician 2003;67:1392, 1395-1397
84. Geraud G, Lanteri-Minet M, Lucas C, et al. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004;26:1305-1318
85. Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 1996;174:823-828
86. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56:335-340
87. Sorensen HT, Steffensen FH, Olesen C, et al. Pregnancy outcome in women exposed to calcium channel blockers. Reprod Toxicol 1998;12:383-384
88. Weber-Schoendorfer C, Hannemann D, Meister R, et al. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol 2008;26:24-30
89. Bott-Kanner G, Schweitzer A, Schoenfeld A, et al. Treatment with propranolol and hydralazine throughout pregnancy in a hypertensive patient. A case report. Ir J Med Sci 1978;14:466-468
90. O'Connor PC, Jick H, Hunter JR, et al. Propranolol and pregnancy outcome. Lancet 1981;2:1168
91. Campbell JW. A possible teratogenic effect of propranolol. N Engl J Med 1985;313:18
92. Redmond GP. Propranolol and fetal growth retardation. Semin Perinatol 1982;6:142-147
93. Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999;12:541-547
94. Bayliss H, Churchill D, Beevers M, et al. Anti-hypertensive drugs in pregnancy and fetal growth: evidence for "pharmacological programming" in the first trimester? Hypertens Pregnancy 2002;21:161-174
95. Easterling TR, Carr DB, Brateng D, et al. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 2001;98:427-433
96. Tabacova S, Kimmel CA, Wall K, et al. Atenolol developmental toxicity: animal-to-human comparisons. Birth Defects Res A Clin Mol Teratol 2003;67:181-192
97. Ghanem FA, Movahed A. Use of antihypertensive drugs during pregnancy and lactation. Cardiovasc Ther 2008;26:38-49
98. Lewis AJ, Galbally M, Opie G, et al. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust NZ J Psychiatry 2010;44:482-487
99. Santone G, Ricchi G, Rocchetti D, et al. Is the exposure to antidepressant drugs in early pregnancy a risk factor for spontaneous abortion? A review of available evidences. Epidemiol Psichiatr Soc 2009;18:240-247
100. Toh S, Mitchell AA, Louik C, et al. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009;29:555-560
101. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006;21:221-222
102. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;5:1-11
103. Webster PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973;2:318-319
104. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995;15:417-420
105. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89:713-718
106. Nordeng H, Lindemann R, Perminov KV, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-291
107. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-2383 (Pubitemid 40676760)
108. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482-487
109. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-587 (Pubitemid 43209105)
110. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-176
111. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-2451
112. Cooper WO. Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors. J Cardiovasc Nurs 2008;23:20-24
113. From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995. JAMA 1997;277:1193-1194
114. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol 1992;80:429-432
115. Kreft-Jais C, Plouin PF, Tchobroutsky C, et al. Angiotensin-converting enzyme inhibitors during pregnancy: a survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynaecol 1988;95:420-422
116. Lip GY, Churchill D, Beevers M, et al. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 1997;350:1446-1447
117. Steffensen FH, Nielsen GL, Sorensen HT, et al. Pregnancy outcome with ACE-inhibitor use in early pregnancy. Lancet 1998;351:596
118. Ray JG, Vermeulen MJ, Koren G. Taking ACE inhibitors during early pregnancy: is it safe? Can Fam Physician 2007;53:1439-1440
119. Cunniff C, Jones KL, Phillipson J, et al. Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use. Am J Obstet Gynecol 1990;162:187-189
120. Rosa FW, Bosco LA, Graham CF, et al. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol 1989;74:371-374
121. Hanssens M, Keirse MJ, Vankelecom F, et al. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991;78:128-135
122. Burrows RF, Burrows EA. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust NZ J Obstet Gynaecol 1998;38:306-311
123. Easterling TR, Carr DB, Davis C, et al. Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. Obstet Gynecol 2000;96:956-961
124. Tabacova S, Little R, Tsong Y, et al. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 2003;12:633-646
125. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006;82:23-28
126. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005;73:123-130
127. Martin U, Foreman MA, Travis JC, et al. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 2008;33:507-511
128. Riaz M, Porat R, Brodsky NL, et al. The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study. J Perinatol 1998;18:449-454
129. Paulson GW. Headaches in women, including women who are pregnant. Am J Obstet Gynecol 1995;173:1734-1741
130. Merlob P, Stahl B. Classification of drugs for teratogenic risk: an anachronistic way of counseling. Teratology 2002;66:61-62
131. Clementi M, Cassina M, Di Gianantonio E. Medications in pregnancy and lactation. Obstet Gynecol 2009;114:166